NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2017.
Dr. Lindsay A. Rosenwald, Fortress’ Chairman, President and Chief Executive Officer, said, “Fortress enjoyed strong third quarter performance, beginning with the formation of a new gene therapy subsidiary company, Aevitas Therapeutics. Fortress’ other subsidiaries also continued to achieve important corporate and clinical milestones during the quarter. Avenue dosed the first patient in its pivotal Phase 3 study of IV tramadol for the management of moderate to moderately severe pain in patients following bunionectomy surgery. Additionally, Checkpoint dosed the first patient in its Phase 1 clinical study evaluating the safety and tolerability of its anti-PD-L1 antibody, CK-301, in selected recurrent or metastatic cancers. The FDA also granted Orphan Drug Designation to Checkpoint’s third-generation EGFR inhibitor, CK-101, for the treatment of EGFR mutation-positive NSCLC. Mustang Bio has continued to make meaningful progress throughout the quarter, with its common stock commencing trading on the NASDAQ Global Market, and the licensing of a CD20 CAR T cell therapy from the Fred Hutchinson Cancer Research Center, expanding its pipeline to six novel CAR T candidates.”
Dr. Rosenwald continued, “We look forward to oral data presentations on both Mustang Bio’s and Caelum Biosciences’ clinical programs at the 59th American Society of Hematology Annual Meeting in December, and plan to continue delivering on meaningful milestones for the remainder of the year.”
Financial Results:
- As of September 30, 2017, Fortress’ consolidated cash, cash equivalents and short-term investments totaled $154.6 million, compared to $88.3 million at December 31, 2016, an increase of $66.3 million year-to-date. The September 30, 2017 consolidated cash, cash equivalents and short-term investments total excludes restricted cash of $16.9 million and cash deposits with clearing organizations of $1.0 million.
- Net revenue totaled $46.9 million for the third quarter of 2017 and $142.3 million for the first nine months of 2017, compared to $1.0 million for the third quarter of 2016 and $3.9 million for the first nine months of 2016. Net total revenue for the third quarter ending September 30, 2017 includes $2.5 million of Fortress revenue and $44.4 million of revenue from National Holdings Corporation (“National”), which Fortress acquired in September 2016, with no revenue attributable to National prior to the acquisition.
- Research and development expenses were $15.9 million for the third quarter of 2017, of which $14.2 million was related to Fortress Companies, and $34.7 million for the first nine months of 2017, of which $29.1 million was related to Fortress Companies. This compares to $7.3 million for the third quarter of 2016, of which $5.5 million was related to Fortress Companies, and $21.4 million for the first nine months of 2016, of which $15.8 million was related to Fortress Companies. Non-cash stock-based compensation expense included in research and development for the third quarter of 2017 was $1.6 million, compared to $0.9 million for the third quarter of 2016, and $4.8 million for the first nine months of 2017, compared to $3.4 million for the first nine months of 2016.
- Research and development expenses from license acquisitions totaled $0.3 million for the third quarter of 2017 and $3.4 million for the first nine months of 2017, compared to $1.0 million for the third quarter of 2016 and $3.1 million for the first nine months of 2016.
- General and administrative expenses were $15.1 million for the third quarter of 2017, of which $10.9 million was related to Fortress Companies, and $36.5 million for the first nine months of 2017, of which $23.8 million was related to Fortress Companies. This compares to $8.9 million for the third quarter of 2016, of which $3.8 million was related to Fortress Companies, and $25.4 million for the first nine months of 2016, of which $11.5 million was related to Fortress Companies. Non-cash stock-based compensation expenses included in general and administrative expenses were $2.6 million for the third quarter of 2017, compared to $2.0 million for the third quarter of 2016, and $6.9 million for the first nine months of 2017, compared to $5.4 million for the first nine months of 2016.
- National’s operating expenses totaled $47.7 million for the third quarter of 2017 and $139.2 million for the first nine months of 2017, with no expenses attributable to National prior to Fortress’ acquisition of the company in September 2016.
- Net loss attributable to common stockholders was $27.1 million, or $0.67 per share, for the third quarter of 2017, compared to a net loss attributable to common stockholders of $13.0 million, or $0.32 per share, for the third quarter of 2016. For the first nine months of 2017, net loss attributable to common stockholders was $56.5 million or $1.39 per share, compared to a net loss attributable to common stockholders of $37.7 million or $0.94 per share in the first nine months of 2016.
Recent Fortress Biotech and Fortress Company Highlights:
Fortress Biotech, Inc.
- In November 2017, Fortress announced that it priced an underwritten public offering of one million shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $25.00 per share, with expected gross proceeds to Fortress of $25 million. In addition, Fortress granted the underwriters a 30-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 14, 2017, subject to customary closing conditions.
- In July 2017, Fortress formed a new subsidiary company, Aevitas Therapeutics, Inc. (“Aevitas”), to develop novel gene therapy approaches for complement-mediated diseases. The proprietary technology, licensed from a leading university, uses adeno-associated virus (AAV)-based gene therapy to restore lasting production of functional complement regulatory proteins, providing a potentially curative treatment.
Avenue Therapeutics, Inc.
- In September 2017, Avenue announced that the first patient had been dosed in the pivotal Phase 3 clinical trial of intravenous (IV) tramadol for the management of moderate to moderately severe pain in patients following bunionectomy surgery.
Caelum Biosciences, Inc.
- In November 2017, Caelum announced that Columbia University will present the final analysis of CAEL-101 (11-1F4) Phase 1a/1b data for the treatment of relapsed or refractory amyloid light chain “AL” amyloidosis during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting in December 2017. Caelum licensed the rights to CAEL-101 in January 2017.
- During the third quarter of 2017, Caelum completed a third-party Convertible Note financing. In connection with this financing, Caelum raised $9.9 million.
Cellvation, Inc.
- In November 2017, Cellvation announced that the U.S. Food and Drug Administration (FDA) granted CEVA101 (autologous bone marrow-derived stem cells) Regenerative Medicine Advanced Therapy (“RMAT”) designation for the treatment of traumatic brain injury (“TBI”). Under terms of the RMAT designation, the FDA will help facilitate the program’s expedited development and review, and will provide guidance on generating the evidence needed to support approval of CEVA101 for TBI.
Checkpoint Therapeutics, Inc.
- In October 2017, Checkpoint announced that the first patient had been dosed in a Phase 1 clinical study evaluating the safety and tolerability of its anti-PD-L1 antibody, CK-301, in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers.
- In September 2017, Checkpoint announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
Mustang Bio, Inc.
- In November 2017, Mustang announced that its research and development partner, City of Hope (“COH”), will present initial Phase 1 data for MB-102 (CD123 CAR) in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) during an oral session at the ASH Annual Meeting.
- In October 2017, Mustang announced that preclinical data for MB-103, its second-generation HER2 CAR T cell therapy, were published online in Clinical Cancer Research, a journal of the American Association for Cancer Research. These preclinical data from a study conducted by COH demonstrate effective targeting of breast cancer brain metastases with intraventricular delivery of HER2-BBζ CAR T cells, and support the clinical development of this therapy.
- In October 2017, Mustang entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the Company’s CAR T product candidates. The facility is expected to be operational for the production of personalized CAR T therapies in 2018.
- In October 2017, Mustang announced that COH received a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund an ongoing Phase 1 study of Mustang’s MB-101 (IL13Rα2‐specific CAR T cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.
- In September 2017, Mustang announced an exclusive, worldwide licensing agreement with Fred Hutchinson Cancer Research Center (“Fred Hutch”) for the use of a CAR T therapy related to autologous T cells engineered to express a CD20-specific chimeric antigen receptor (“CD20 Technology”). The CAR T was developed in the laboratory of Oliver Press, M.D., Ph.D., and Brian Till, M.D., in Fred Hutch’s Clinical Research Division. As part of the transaction, Mustang entered into an investigator-initiated clinical trial agreement to provide partial funding for a Phase 1/2 clinical trial at Fred Hutch evaluating the safety and efficacy of the CD20 Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. The trial began recruiting participants in the fourth quarter of 2017, and is led by principal investigator Mazyar Shadman, M.D., Assistant Member of Fred Hutch’s Clinical Research Division.
- In August 2017, Mustang’s common stock commenced trading on the NASDAQ Global Market under the symbol “MBIO.”
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensing arrangements, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com
Fortress Biotech Media Relations
Laura Bagby
6 Degrees
(312) 448-8098
lbagby@6degreespr.com
FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
($ in thousands except for share and per share amounts)
| September 30, | December 31, | |||||||||||||
| 2017 | 2016 | |||||||||||||
| (Unaudited) | ||||||||||||||
| ASSETS | ||||||||||||||
| Current assets | ||||||||||||||
| Cash and cash equivalents | $ | 110,536 | $ | 88,294 | ||||||||||
| Accounts receivable | 5,582 | 1,830 | ||||||||||||
| Short-term investment (certificate of deposit) | 44,088 | - | ||||||||||||
| Cash deposits with clearing organizations | 1,040 | 1,030 | ||||||||||||
| Receivables from broker-dealers and clearing organizations | 8,282 | 3,357 | ||||||||||||
| Forgivable loans receivable | 1,269 | 1,712 | ||||||||||||
| Securities owned, at fair value | 1,595 | 2,357 | ||||||||||||
| Inventory | 318 | 203 | ||||||||||||
| Other receivables - related party | 638 | 1,790 | ||||||||||||
| Prepaid expenses and other current assets | 10,739 | 9,061 | ||||||||||||
| Total current assets | 184,087 | 109,634 | ||||||||||||
| Property and equipment, net | 8,221 | 7,376 | ||||||||||||
| Restricted cash | 16,886 | 15,860 | ||||||||||||
| Long-term investments, at fair value | 923 | 1,414 | ||||||||||||
| Intangible asset - license | 15,983 | 17,408 | ||||||||||||
| Goodwill | 18,645 | 18,645 | ||||||||||||
| Other assets | 346 | 394 | ||||||||||||
| Total assets | $ | 245,091 | $ | 170,731 | ||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||
| Current liabilities | ||||||||||||||
| Accounts payable and accrued expenses | $ | 31,978 | $ | 23,871 | ||||||||||
| Accrued expense - related party | 88 | - | ||||||||||||
| Accrued commissions and payroll payable | 11,255 | 11,940 | ||||||||||||
| Deferred clearing and marketing credits | 838 | 995 | ||||||||||||
| Deferred product revenue | 680 | - | ||||||||||||
| Securities sold, not yet purchased, at fair value | - | 298 | ||||||||||||
| Interest payable | 161 | 88 | ||||||||||||
| Interest payable - related party | 497 | 77 | ||||||||||||
| Notes payable, short-term (net of debt discount of $1,277 and $0 at September 30, 2017 and December 31, 2016, respectively) | 8,223 | 1,000 | ||||||||||||
| Subsidiary convertible note, short-term, at fair value | 4,733 | 1,031 | ||||||||||||
| Contingent consideration payable | 637 | 424 | ||||||||||||
| Warrants issued in 2017 and issuable in 2016 - National | 8,832 | 14,359 | ||||||||||||
| Contingently issuable liabilities | - | 1,682 | ||||||||||||
| Derivative warrant liability | 313 | 481 | ||||||||||||
| Other current liabilities | 193 | 319 | ||||||||||||
| Total current liabilities | 68,428 | 56,565 | ||||||||||||
| Notes payable, long-term (net of debt discount of $2,550 and $2,009 at September 30, 2017 and December 31, 2016, respectively) | 40,734 | 22,528 | ||||||||||||
| Subsidiary convertible note, long-term, at fair value | 9,928 | 3,656 | ||||||||||||
| Other long-term liabilities | 4,736 | 5,014 | ||||||||||||
| Total liabilities | 123,826 | 87,763 | ||||||||||||
| Commitments and contingencies | ||||||||||||||
| Stockholders' equity | ||||||||||||||
| Convertible preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively | - | - | ||||||||||||
| Common stock, $.001 par value, 100,000,000 shares authorized, 50,584,937 and 48,932,023 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively | 51 | 49 | ||||||||||||
| Common stock issuable, 86,272 and 0 shares as of September 30, 2017 and December 31, 2016, respectively | 353 | - | ||||||||||||
| Additional paid-in-capital | 338,254 | 283,697 | ||||||||||||
| Accumulated deficit | (301,714 | ) | (245,251 | ) | ||||||||||
| Total stockholders' equity attributed to the Company | 36,944 | 38,495 | ||||||||||||
| Non-controlling interests | 84,321 | 44,473 | ||||||||||||
| Total stockholders' equity | 121,265 | 82,968 | ||||||||||||
| Total liabilities and stockholders' equity | $ | 245,091 | $ | 170,731 | ||||||||||
FORTRESS BIOTECH, INC. AND SUBSIDIARIES
Condensed Consolidated Statement of Operations
($ in thousands except for share and per share amounts)
(Unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||
| Revenue | ||||||||||||||||
| Fortress | ||||||||||||||||
| Product revenue, net | $ | 2,170 | $ | 429 | $ | 8,309 | $ | 1,793 | ||||||||
| Revenue - from a related party | 350 | 546 | 1,393 | 2,072 | ||||||||||||
| Net Fortress revenue | 2,520 | 975 | 9,702 | 3,865 | ||||||||||||
| National | ||||||||||||||||
| Commissions | 24,881 | - | 73,380 | - | ||||||||||||
| Net dealer inventory gains | 1,789 | - | 6,666 | - | ||||||||||||
| Investment banking | 8,942 | - | 26,595 | - | ||||||||||||
| Investment advisory | 3,605 | - | 10,480 | - | ||||||||||||
| Interest and dividends | 674 | - | 2,065 | - | ||||||||||||
| Transfer fees and clearing services | 1,649 | - | 5,834 | - | ||||||||||||
| Tax preparation and accounting | 2,527 | - | 6,527 | - | ||||||||||||
| Other | 299 | - | 1,016 | - | ||||||||||||
| Total National revenue | 44,366 | - | 132,563 | - | ||||||||||||
| Net revenue | 46,886 | 975 | 142,265 | 3,865 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Fortress | ||||||||||||||||
| Cost of goods sold - product revenue | 505 | 41 | 1,852 | 365 | ||||||||||||
| Research and development | 15,890 | 7,316 | 34,683 | 21,416 | ||||||||||||
| Research and development – licenses acquired | 300 | 1,000 | 3,394 | 3,143 | ||||||||||||
| General and administrative | 15,104 | 8,864 | 36,490 | 25,414 | ||||||||||||
| Total Fortress operating expenses | 31,799 | 17,221 | 76,419 | 50,338 | ||||||||||||
| National | ||||||||||||||||
| Commissions, compensation and fees | 39,963 | - | 118,983 | - | ||||||||||||
| Clearing fees | 470 | - | 1,826 | - | ||||||||||||
| Communications | 690 | - | 2,094 | - | ||||||||||||
| Occupancy | 972 | - | 2,916 | - | ||||||||||||
| Licenses and registration | 391 | - | 1,223 | - | ||||||||||||
| Professional fees | 1,082 | - | 3,336 | - | ||||||||||||
| Interest | 5 | - | 13 | - | ||||||||||||
| Depreciation and amortization | 507 | - | 1,513 | - | ||||||||||||
| Other administrative expenses | 3,610 | - | 7,315 | - | ||||||||||||
| Total National operating expenses | 47,690 | - | 139,219 | - | ||||||||||||
| Total operating expenses | 79,489 | 17,221 | 215,638 | 50,338 | ||||||||||||
| Loss from operations | (32,603 | ) | (16,246 | ) | (73,373 | ) | (46,473 | ) | ||||||||
| Other income (expenses) | ||||||||||||||||
| Interest income | 204 | 89 | 530 | 241 | ||||||||||||
| Interest expense and financing fee | (3,220 | ) | (689 | ) | (5,298 | ) | (1,838 | ) | ||||||||
| Change in fair value of derivative liabilities | (639 | ) | (16 | ) | 5,155 | (105 | ) | |||||||||
| Change in fair value of subsidiary convertible note | (74 | ) | (13 | ) | (359 | ) | (13 | ) | ||||||||
| Change in fair value of investments | 270 | (81 | ) | (241 | ) | (1,800 | ) | |||||||||
| Other expenses | (245 | ) | - | (232 | ) | - | ||||||||||
| Total other income (expenses) | (3,704 | ) | (710 | ) | (445 | ) | (3,515 | ) | ||||||||
| Net loss | (36,307 | ) | (16,956 | ) | (73,818 | ) | (49,988 | ) | ||||||||
| Less: net loss attributable to non-controlling interests | 9,191 | 3,975 | 17,355 | 12,324 | ||||||||||||
| Net loss attributable to common stockholders | $ | (27,116 | ) | $ | (12,981 | ) | $ | (56,463 | ) | $ | (37,664 | ) | ||||
| Basic and diluted net loss per common share | $ | (0.67 | ) | $ | (0.32 | ) | $ | (1.39 | ) | $ | (0.94 | ) | ||||
| Weighted average common shares outstanding—basic and diluted | 40,724,115 | 40,128,475 | 40,547,364 | 39,885,685 | ||||||||||||